LJM2

LJM2
Name	LJM2

LJM2

LJM2 is a biomolecule characterized in molecular and cellular biology contexts and referenced across biochemical, biomedical, and translational research literatures. It has been examined in structural studies, genetic analyses, and disease-association investigations spanning model organisms and clinical cohorts. Work on LJM2 interfaces with multiple fields including proteomics, genomics, cell signaling, and pathology.

Definition and Nomenclature

LJM2 is designated by a short alphanumeric symbol used in gene and protein nomenclature registries and appears in databases curated by organizations such as GenBank, Ensembl, UniProt, NCBI Gene, and HGNC. Historical aliases and transcript variants have been cataloged in resources including RefSeq, CCDS, PDB, and locus-specific databases maintained by institutions like EMBL-EBI and UCSC Genome Browser. The naming convention follows standards set by committees akin to HGNC for human genes and corresponding bodies for model organisms such as MGI for mouse and ZFIN for zebrafish.

History and Discovery

LJM2 emerged in the literature following high-throughput sequencing and proteomics efforts exemplified by initiatives like the Human Genome Project, ENCODE Project, and large-scale mass spectrometry surveys by groups collaborating with PRIDE Archive. Initial identification traces to transcriptomic screens performed in labs associated with institutions such as Broad Institute, Sanger Institute, and university centers that participated in consortia like GTEx and TCGA. Functional annotation developed through follow-on studies at research hubs including Max Planck Society, Cold Spring Harbor Laboratory, and clinical research centers at universities such as Harvard University and Johns Hopkins University.

Structure and Mechanism

Structural characterization of LJM2 has been pursued using methods common to structural biology communities, including X-ray crystallography at facilities like Advanced Photon Source and cryo-electron microscopy at centers such as EMBL and MRC Laboratory of Molecular Biology. Models and domain annotations are deposited to repositories like Protein Data Bank and cross-referenced with motif databases maintained by InterPro and Pfam. Mechanistic hypotheses integrate insights from signaling work in pathways studied at institutions including MIT, Stanford University, and University of California, San Francisco, and often invoke interactions with partners cataloged in interaction databases used by groups such as BioGRID and STRING.

Biological Function and Expression

Expression profiling for LJM2 employs platforms and projects such as GTEx, TCGA, ArrayExpress, and single-cell atlases produced by collaborations linked to Human Cell Atlas. Tissue-, cell type-, and developmental-stage–specific expression patterns have been compared to markers characterized in studies at Karolinska Institutet and Massachusetts General Hospital. Functional studies reference pathways and networks familiar to researchers at institutes like Wellcome Trust Sanger Institute and European Molecular Biology Laboratory, and draw parallels with molecules studied in cancer research at centers such as MD Anderson Cancer Center and Dana-Farber Cancer Institute.

Clinical Significance and Disease Associations

Clinical associations of LJM2 have been explored in cohort studies coordinated with entities like National Institutes of Health, Centers for Disease Control and Prevention, and registries supported by foundations such as American Cancer Society and American Heart Association. Variants and mutations have been cross-referenced against clinical resources including ClinVar, OMIM, and population databases compiled by 1000 Genomes Project and gnomAD. Disease models and patient-derived studies have been conducted in collaboration with hospitals and research centers such as Mayo Clinic, Cleveland Clinic, and university hospitals affiliated with University College London and Karolinska University Hospital.

Research Tools and Experimental Models

Experimental investigation of LJM2 uses tools and models widely adopted across life-science labs: CRISPR systems developed by labs including those at Broad Institute and Jennifer Doudna-associated groups, RNAi approaches standardized in studies from Whitehead Institute, and animal models maintained by repositories like Jackson Laboratory and European Mouse Mutant Archive. Cell lines utilized in LJM2 research include well-characterized lines cataloged by ATCC and primary tissues accessed through biobanks such as UK Biobank and Biobank Japan. Proteomic, genomic, and imaging platforms supporting LJM2 studies are operated at core facilities affiliated with institutions like Stanford],] Yale University, and University of Cambridge.

Category:Proteins